Hcw Biologics, Inc. (HCWB)
NASDAQ:HCWB
Want to see HCWB full AI Analyst Report?
Top Page
HCW Biologics
(NASDAQ:HCWB)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.43
▼(-89.32% Downside)
Action:ReiteratedDate:04/28/26
HCWB scores low primarily due to weak financial performance (sharp revenue decline, very large losses, and persistent cash burn with balance-sheet strain). Technicals remain soft overall (below key longer-term averages and negative MACD), while valuation is difficult to justify with negative earnings. Corporate events are a modest positive (license cash and compliance) but are outweighed by continued funding/dilution dependence.
Positive Factors
Non-dilutive licensing & China JV
The $7M upfront license and equity stake with Beijing Trimmune shifts Phase‑1 development costs to a partner, delivering non‑dilutive cash and milestone/royalty upside. This materially reduces near‑term burn, preserves capital for core programs, and provides regional de‑risking and potential co‑development optionality.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow necessitates repeated external financing, increasing dilution risk and limiting strategic optionality. Even with modest improvement, continued cash burn constrains runway, forces prioritization of programs, and raises the likelihood of unfavourable funding terms over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive licensing & China JV
The $7M upfront license and equity stake with Beijing Trimmune shifts Phase‑1 development costs to a partner, delivering non‑dilutive cash and milestone/royalty upside. This materially reduces near‑term burn, preserves capital for core programs, and provides regional de‑risking and potential co‑development optionality.
Read all positive factors
HCW Biologics (HCWB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.74M
Dividend YieldN/A
Average Volume (3M)16.84M
Price to Earnings (P/E)0.7
Beta (1Y)1.42
Revenue Growth-97.89%
EPS Growth62.56%
CountryUS
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.02
Shares Outstanding6,734,104
10 Day Avg. Volume553,306
30 Day Avg. Volume16,842,751
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.54
P/FCF Ratio-0.15
Enterprise Value/Market Cap2.08
Enterprise Value/Revenue105.23
Enterprise Value/Gross Profit-35.00
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$2.00Price Target Upside-49.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$900.00K
HCW Biologics Business Overview & Revenue Model
Company Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an ...
How the Company Makes Money
null...
HCW Biologics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
32
Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.23K | 2.57M | 2.84M | 6.72M | 0.00 |
| Gross Profit | 10.85K | 959.40K | 560.36K | 2.59M | -543.60K |
| EBITDA | -5.67M | -27.68M | -23.58M | -14.06M | -12.32M |
| Net Income | -7.96M | -30.02M | -24.99M | -14.90M | -12.86M |
Balance Sheet | |||||
| Total Assets | 24.52M | 30.24M | 28.51M | 46.81M | 53.51M |
| Cash, Cash Equivalents and Short-Term Investments | 1.95M | 4.67M | 3.60M | 32.06M | 36.71M |
| Total Debt | 6.81M | 13.69M | 6.30M | 6.41M | 0.00 |
| Total Liabilities | 21.76M | 37.01M | 15.05M | 9.38M | 2.32M |
| Stockholders Equity | 2.76M | -6.77M | 13.46M | 37.43M | 51.19M |
Cash Flow | |||||
| Free Cash Flow | -13.39M | -14.49M | -28.72M | -20.66M | -11.02M |
| Operating Cash Flow | -13.39M | -14.23M | -22.51M | -10.39M | -10.98M |
| Investing Cash Flow | 0.00 | -261.62K | 3.80M | 14.71M | -35.02M |
| Financing Cash Flow | 10.67M | 15.57M | -14.53K | 6.27M | 49.27M |
HCW Biologics Technical Analysis
Neutral
3.99
Price Trends
0.58
Negative
1.05
Negative
2.56
Negative
Market Momentum
-0.07
Negative
47.99
Neutral
101.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCWB, the sentiment is Neutral. The current price of 3.99 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.58, and above the 200-day MA of 2.56, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 47.99 is Neutral, neither overbought nor oversold. The STOCH value of 101.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HCWB.
HCW Biologics Risk Analysis
HCW Biologics disclosed 48 risk factors in its most recent earnings report. HCW Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
HCW Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $9.28M | -0.31 | -32.58% | ― | -100.00% | -245.22% | |
51 Neutral | $6.87M | -1.38 | -60.33% | ― | 19.04% | 37.12% | |
51 Neutral | $9.16M | -1.12 | -71.27% | ― | -72.15% | -223.53% | |
44 Neutral | $2.74M | 0.71 | 400.16% | ― | -97.89% | 62.56% | |
42 Neutral | $3.93M | -0.42 | -157.24% | ― | ― | 58.93% | |
41 Neutral | $2.27M | -0.52 | ― | ― | ― | 84.28% |
* Healthcare Sector Average
HCWB
HCW Biologics
0.41
-7.65
-94.95%
KPRX
Kiora Pharmaceuticals
2.35
-0.87
-27.02%
MTNB
Matinas BioPharma
0.61
0.02
3.90%
XBIO
Xenetic Biosciences
3.00
0.16
5.63%
ADXN
Addex Therapeutics
7.00
-0.79
-10.14%
CLDI
Calidi Biotherapeutics
0.21
-5.58
-96.41%
HCW Biologics Corporate Events
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
HCW Biologics Lowers Shareholder Meeting Quorum Requirement
Neutral
Apr 16, 2026
On April 15, 2026, HCW Biologics Inc.’s board approved an amendment to its Bylaws that will take effect on April 28, 2026, lowering the shareholder quorum requirement for conducting business at meetings. The new standard sets a quorum at 33 ...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Secures $7M License Deal for HCW11-006
Positive
Mar 17, 2026
On March 17, 2026, HCW Biologics Inc., a U.S.-based commercial- and clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune disease, cancer and senescence-associated dysplasia, reported it had received full paymen...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight
Positive
Mar 2, 2026
HCW Biologics Inc., a clinical-stage biopharmaceutical developer of novel immunotherapies targeting chronic inflammation and age-related, senescence-associated diseases, is advancing a pipeline led by HCW9302, an IL-2 fusion molecule in Phase 1 fo...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Completes Follow-On Offering to Fund Pipeline
Positive
Feb 19, 2026
On February 17, 2026, HCW Biologics Inc. entered into a securities purchase agreement with a single institutional investor for a follow-on public offering of 2,477,292 units, each comprising a common share or pre-funded warrant plus a common stock...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Licenses TRBC Asset to China JV Trimmune
Positive
Feb 13, 2026
On February 13, 2026, HCW Biologics and China-based WY Biotech announced an exclusive worldwide license agreement granting newly formed Beijing Trimmune Biotech rights to develop and commercialize in vivo applications of HCW11-006, a preclinical T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.